Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 10:6:17850.
doi: 10.1038/srep17850.

The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates

Affiliations

The diagnostic accuracy of the MTBDRplus and MTBDRsl assays for drug-resistant TB detection when performed on sputum and culture isolates

Michele Tomasicchio et al. Sci Rep. .

Abstract

Although molecular tests for drug-resistant TB perform well on culture isolates, their accuracy using clinical samples, particularly from TB and HIV-endemic settings, requires clarification. The MTBDRplus and MTBDRsl line probe assays were evaluated in 181 sputum samples and 270 isolates from patients with culture-confirmed drug-sensitive-TB, MDR-TB, or XDR-TB. Phenotypic culture-based testing was the reference standard. Using sputum, the sensitivities for resistance was 97.7%, 95.4%, 58.9%, 61.6% for rifampicin, isoniazid, ofloxacin, and amikacin, respectively, whereas the specificities were 91.8%, 89%, 100%, and 100%, respectively. MTBDRsl sensitivity differed in smear-positive vs. smear-negative samples (79.2% vs. 20%, p < 0.0001 for ofloxacin; 72.9% vs. 37%, p = 0.0023 for amikacin) but not by HIV status. If used sequentially, MTBDRplus and MTBDRsl could rule-in XDR-TB in 78.5% (22/28) and 10.5% (2/19) of smear-positive and smear-negative samples, respectively. On culture isolates, the sensitivity for resistance to rifampicin, isoniazid, ofloxacin, and amikacin was 95.1%, 96.1%, 72.3% and 76.6%, respectively, whereas the specificities exceeded 96%. Using a sequential testing approach, rapid sputum-based diagnosis of fluoroquinolone or aminoglycoside-resistant TB is feasible only in smear-positive samples, where rule-in value is good. Further investigation is required in samples that test susceptible in order to rule-out second-line drug resistance.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Study plan showing the number of sputum samples tested directly using MTBDRplus (version 1) or MTBDRsl (version 1) according to patients’ diagnoses and smear-status.
The diagnosis was obtained using phenotypic liquid culture-based DST on a specimen collected at the same time as the specimen used for the line probe assays. A test is classified as positive for the Mycobacterium tuberculosis complex by the presence of the M. tb complex band (TUB), while a test is classified as negative by the absence of the M. tb complex band (TUB). Indeterminate results are those which are TUB-band positive yet are missing controls bands for gene specific loci. TB = tuberculosis; DS = drug sensitive, MDR = multi drug resistant, MDR+ =  MDR-TB but with additional resistance to OFX, KAN or INH. XDR = extensively drug resistant.
Figure 2
Figure 2
The testing pathway for the diagnosis of XDR-TB overall (A) or according to smear-status (B) in the clinical sputum specimens, when MTBDRplus and MTBDRsl were used sequentially. From the 234 sputum specimens tested, 47 culture-positive samples were diagnosed as XDR-TB by phenotypic DST.

Similar articles

Cited by

References

    1. World Health Organisation. Tuberculosis Fact Sheet Number 104 (2014). Available at: www.who.int/mediacentre/factsheets/fs104/en (Accessed: 5th June 2014).
    1. World Health Organization. WHO Global Task Force outlines measures to combat XDR-TB worldwide (2014). Available at: http://www.who.int/mediacentre/news/notes/2006/np29/en/ (Accessed on: 5th June 2014).
    1. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep. 55, 301–305 (2006). - PubMed
    1. Ahuja S. D. et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis. PLoS med. 9, e1001300 (2012). - PMC - PubMed
    1. Dheda K. et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet. 375, 1798–1807 (2010). - PubMed

LinkOut - more resources